Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

N/ANon-phased studies

1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Other(2)

Detailed Status

Completed2

unknown2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed250%

unknown250%

Recent Activity

0 active trials

Showing 4 of 4

completed

Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo

NCT04408014

completednot_applicable

Serology COVID-19 From the Cornwall Hospital Union

NCT04363593

unknown

Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases

NCT04530461

unknown

Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.

NCT04345315

Clinical Trials (4)

Showing 4 of 4 trials

NCT04408014

Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo

Completed

NCT04363593Not Applicable

Serology COVID-19 From the Cornwall Hospital Union

Completed

NCT04530461

Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases

Unknown

NCT04345315

Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.

Unknown

All 4 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 4